Medications Medications

Pharmacological therapy for acute coronary syndrome (ACS) aims to maximise heart function by minimising areas of ischaemia and atherosclerotic progression. Medicines may also be used to facilitate other interventions, e.g., antiplatelet treatment to facilitate coronary stenting. However, medicines are not a substitute for evidence-based lifestyle interventions.

Acute coronary syndrome (ACS) refers to unstable angina, non-ST elevated myocardial infarction (NSTEMI) and ST elevated myocardial infarction (STEMI).

ACS is typically caused by occlusion of coronary vessels following atherosclerotic plaque disruption with subsequent thrombus formation. For more information see pathophysiology of ACS.

For further guidance refer to the ACS Treatment Algorithm

Antithrombotic medications either prevent or break down a thrombus. Preventing thrombus formation with antiplatelet agents and anticoagulants is preferable to using thrombolytics to dissolve an existing thrombus that has already damaged the myocardium. Additionally, the risk of major bleeding is much greater for thrombolytics than antiplatelets or anticoagulants. Acute myocardial infarction (i.e., STEMI), where 'time is muscle', requires an aggressive approach using multiple antithrombotics.

The figure below shows three pathways for managing pathological clot formation:

  • Antiplatelet medications block platelet aggregation in fast-flowing arteries, such as the coronary arteries, where thrombosis is primarily initiated by platelet activation.
    Aspirin works at a different site on platelets to the thienopyridines (clopidogrel and prasugrel) and ticagrelor, and thus a synergistic antiplatelet effect is provided when used together. All these treatments are orally administered. Combination therapy is used when thrombotic risk is high, such as after stent implantation, but carries a higher risk of bleeding.
  • Intravenous (IV) glycoprotein IIb/IIIa receptor antagonists (abciximab, tirofiban) are antiplatelet agents that block the final stage in platelet aggregation.
  • Anticoagulant medications are preferable in low-flow vessels to prevent clot formation such as in atrial fibrillation (AF) and deep vein thrombus (DVT). Thrombus prevention in ACS patients with AF, particularly those with stenting, is especially challenging in terms of aiming to balance efficacy and safety when using combined antithrombotics.
    Patients with a STEMI or a high-risk NSTEMI are given a fast-acting anticoagulant (IV or subcutaneous (sc) heparin or a sc low molecular weight heparin such as enoxaparin, dalteparin and nadroparin) to prevent thrombin production. This in turn inhibits fibrin generation and subsequent thrombus extension.
  • Thrombolytics lyse or break down the thrombus. In patients with STEMI, a thrombolytic may also be added (commonly IV tenecteplase) if the patient meets certain criteria.

Figure 1: Site of action of antithrombotics


Beta-blockers act on beta-adrenoceptors to antagonise the effects of sympathetic nerve stimulation caused by circulating catecholamines such as adrenaline and noradrenaline. This inhibition reduces the heart rate and the force of heart contraction, subsequently reducing cardiac workload, cardiac output and blood pressure (BP). Beta-blockers also reduce renin production.

Beta-blockers should be started in all patients following STEMI unless absolutely contraindicated. The clinical situation should drive the timing of this treatment. Patients at higher risk of cardiogenic shock, or those with inferior STEMIs, may have beta-blockers delayed for 1-2 days post-STEMI, whereas patients with a rapid ventricular rate and an anterior myocardial infarction (MI) should begin beta-blocker treatment start as soon as possible.

The role of IV beta-blockers in the immediate management of STEMI is controversial; compared with oral beta-blockers, early IV metoprolol in STEMI patients shows significantly reduced rates of reinfarction, ventricular fibrillation (VF) and decreased infarct size, but increased cardiogenic shock. IV beta-blockers are not recommended in the majority of patients with acute STEMI but could be considered in those with significant ventricular arrhythmias or severe BP elevations.

Although limited evidence is available, Australian and international guidelines, however, also recommend routine use of beta-blockers for NSTEMI patients based on observational data and extrapolation from STEMI trials.

Beta-blockers are also first-line agents for stable angina since they reduce systemic arterial pressure, heart rate and myocardial contractility, resulting in reduced myocardial oxygen demand and symptoms.

Beta-blockers should generally be avoided in patients with decompensated HF (e.g., acute pulmonary oedema), heart block or significant bradycardia (heart rate <50 beats per minute (bpm)).

For further beta-blocker treatment considerations see Cautions and monitoring.

Asthma is no longer considered an absolute contraindication for cardioselective beta-blockers such as atenolol, bisoprolol and metoprolol.

However, non-selective beta-blockers such as propranolol and carvedilol should not be used in asthmatics.[#salpeter-sr-ormiston-tm-salpeter-ee-et-al.-2002]

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) act on the renin-angiotensin-aldosterone system (see figure below). ACE inhibitors prevent the endogenous production of angiotensin II, whereas ARBs antagonise the effects of angiotensin II. After a STEMI, where there is reduced left ventricular ejection fraction (LVEF), these medicines work to inhibit pathological left ventricular remodelling.

ACE inhibitors and ARBS also cause peripheral vasodilation, thereby reducing BP.

Figure 2: Components and effects of the renin-angiotensin-aldosterone system


ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ADH = antidiuretic hormone; MRA = mineralocorticoid receptor antagonist

Oral statins (e.g.,atorvastatin, fluvastatin, pravastatin, simvastatin) reduce blood levels of low-density lipoprotein cholesterol (LDL-C), which is a major contributor to atherosclerotic plaque development. They also have other important pleiotropic effects such as plaque stabilisation, antioxidant, anti-inflammatory and antiplatelet effects. These multiple actions mean that statins are used even in ACS patients with normal LDL-C levels and during the acute management phase of ACS.

Statins reduce mortality in patients with NSTEMI and STEMI, and should be routinely prescribed for these patients. They are lifelong medications for patients at high risk of CVD, although the dose may change over time. All patients with ACS are considered 'high risk'.


Nitrates are potent vasodilators. In ACS, nitrates vasodilate the coronary vessels, improving oxygen supply to the heart and peripheral vessels, reducing BP and venous return and, thus, cardiac workload.

Short-acting nitrates such as glyceryl trinitrate (GTN) sublingual tablets or spray are used for symptom control in acute stable angina or ACS. Long-acting nitrates (e.g., GTN patches or isosorbide mononitrate as slow release (SR) tablets) are used to prevent symptoms in stable angina.

Long-acting nitrates have no proven mortality benefits, and their use should be reviewed in patients after percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery where ongoing angina is not expected. These patients should be instructed to seek help immediately if they experience chest pain or ACS-like symptoms.


Morphine is used in STEMI, NSTEMI or unstable angina. This opioid is useful for both its analgesic and potential coronary vasodilating effects. Its vasodilating activity is thought to be secondary to decreasing pain and anxiety, which lowers circulating catecholamines and thereby reduces coronary vasoconstriction.


Routine use of supplemental oxygen for acute chest pain is not recommended as there is insufficient evidence supporting its use and also some evidence to suggest potential harm. Supplemental oxygen may increase coronary vascular resistance, potentially leading to poorer outcomes compared to utilising room air.[#ogara-pt-kushner-fg-ascheim-dd-et-al.-2013] Oxygen therapy should only be instituted for hypoxaemic patients (SpO2 <93%) and those with evidence of shock, in order to correct tissue hypoxia.

Oxygen should be used with caution in patients with chronic obstructive pulmonary disease (COPD) and carbon dioxide retention.

The choice of pharmacological therapy varies depending on the type of heart failure (HF), and often changes as the condition progresses.

The pharmacological treatment of left ventricular HF with reduced ejection fraction (HFrEF) has an extensive evidence base and is well supported by clinical guidelines. While similar medicines are often used to treat HF with preserved ejection fraction (HFpEF); to date there have been no therapies shown to improve survival in this patient group; management primarily focuses on treating the underlying causes and symptom control.

HF may solely involve the left ventricle or affect both the left and right ventricles. Isolated right ventricular HF is commonly due to elevated pressure in the pulmonary artery, either from pulmonary arterial hypertension or lung disease.

Management of isolated right HF depends on the underlying cause, and is outside the scope of the HEART Online resource.

HF results in activation of the renin-angiotensin-aldosterone system (RAAS).  This system attempts to maintain cardiac output by maintaining arterial pressure. While this compensatory process is effective in maintaining cardiac output in the short term, the long term attempt to maintain arterial pressure advances the deterioration in heart function. For further information see Pathophysiology of heart failure.

Medicines that prolong life and reduce morbidity are directed at modifying neurohormonal systems, particularly the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS).  These systems are altered using ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs) and beta-blockers. These medicines are recommended as first line treatment of HFREF. Another class of medicines, Angiotensin Receptor Neprilysin Inhibitors (ARNIs), act by blocking the RAAS as well as promoting the beneficial effects of the natriuretic peptide system (NPS).

Some medicines are used primarily to manage the symptoms of HF by manipulating haemodynamics. These include nitrates (which cause vasodilation), diuretics (which alter blood volume) and digoxin (which increases the force of heart contractions). These medicines generally have little or reduced effect on survival and morbidity compared to medicines targeting the neurohormonal activation present in HFrEF.

ACE inhibitors (ACEIs)

ACE inhibitors act primarily on the renin-angiotensin-aldosterone system by blocking the enzyme known as ACE (angiotensin-converting enzyme). As illustrated in the figure below, ACE is required to convert angiotensin I to angiotensin II. By blocking the production of angiotensin II, ACE inhibitors are effective in reducing vasoconstriction, sodium retention, the release of aldosterone, and the remodelling of the heart.

Figure 3: Components and effects of the renin-angiotensin-aldosterone system


ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ADH = antidiuretic hormone; MRA = mineralocorticoid receptor antagonist

Angiotensin II receptor blockers (ARBs)

ARBs act on the renin-angiotensin-aldosterone system by directly blocking the binding of angiotensin II to the receptor. By blocking the effects of angiotensin II, ARBs reduce vasoconstriction, sodium reabsorption, aldosterone release and the remodelling of the heart.

Mineralocorticoid receptor antagonists (MRAs)

Spironolactone and eplerenone are MRAs that inhibit the hormone aldosterone. By blocking the effects of aldosterone, MRAs reduce fibrosis, hypertrophy and arrhythmogenesis within the heart, as well as sodium reabsorption.


Beta-blockers inhibit the adverse effects of chronic activation of the sympathetic nervous system on the myocardium and vasculature. These adverse actions include ventricular hypertrophy and arrhythmogenesis within the heart, and vasoconstriction, and may be mediated via beta1-receptors, beta2-receptors and/or alpha1-receptors.

Angiotensin Receptor – Neprilysin Inhibitors (ARNI)

Sacubitril/valsartan (Entresto) is a medication in a new drug class called angiotensin receptor-neprilysin inhibitor (ARNI)[#jhund-ps-mcmurray-jj.-the-neprilysin-pathway-in-heart-failure-a-review-and] . Sacubitril (neprilysin inhibitor) increases vasodilatory peptides leading to increased diuresis and natriuresis, and decreased ventricular hypertrophy and remodelling. Valsartan is an angiotensin II receptor blocker (ARB) that inhibits neprilysin induced activation of the RAAS.    It should be noted that as a newer drug class, there may be adverse effects and interactions that have not been reported. It is currently reserved for use in patients with HFrEF who remain symptomatic despite optimised ACEI/ARB and BB therapy.

Preserved ejection fraction is seen in approximately 40-50% of all patients diagnosed with HF. Despite the incidence and prevalence of this type of HF, there is limited evidence to guide pharmacotherapy that has a beneficial effect on survival. The approach is to aggressively manage the conditions that contribute to heart failure with preserved ejection fraction (HFpEF) development, such as hypertension, ischaemic heart disease and diabetes. Therapy that manages fluid retention and abnormal heart rate and rhythms are also often required.